Skip to main content
Premium Trial:

Request an Annual Quote

Caris Life Sciences, Syapse Collaborate on Cancer Data Aggregation

NEW YORK (GenomeWeb) – Caris Life Sciences and software developer Syapse today announced a collaboration to collect molecular and genomic information and combine it with clinical treatment and outcomes data from the Caris Centers of Excellence for Precision Medicine Network.

The project will integrate Caris' Molecular Intelligence tumor profiling service with Syapse's Precision Medicine Platform to provide information to support treatment decisions. Under the terms of the agreement, select members of Caris' COE Network will use Syapse's software to capture key oncology-specific clinical data from electronic medical records, integrate that data with Caris' tumor profiling results, and aggregate the de-identified data into Caris' centralized instance of the Syapse Precision Medicine Platform to share it across the network.

Members will also participate in virtual tumor boards, where they can review cases, receive guidance, and share knowledge with each other.

Caris Molecular Intelligence uses a proprietary 592-gene next-generation sequencing panel, RNA sequencing, immunohistochemistry, and in situ hybridization, among other technologies, to detect biomarkers and provide treatment options associated with them. Caris Life Sciences launched the COE Network to create tumor profiling guidelines and advance precision medicine.

Palo Alto, California-based Syapse offers cloud-based software to support oncology testing. Its customers include the University of California, San Francisco and the Roswell Park Cancer Institute. Last month, it partnered with PierianDx to create an end-to-end genomic testing workflow for hospital pathology labs.